{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:33:21Z","timestamp":1785530001111,"version":"3.56.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T00:00:00Z","timestamp":1524700800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s11095-018-2399-0","type":"journal-article","created":{"date-parts":[[2018,4,26]],"date-time":"2018-04-26T11:32:54Z","timestamp":1524742374000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Dual Receptor Targeting Cell Penetrating Peptide Modified Liposome for Glioma and Breast Cancer Postoperative Recurrence Therapy"],"prefix":"10.1007","volume":"35","author":[{"given":"Yue","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajing","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengze","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuping","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,26]]},"reference":[{"issue":"3","key":"2399_CR1","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.nurt.2009.04.006","volume":"6","author":"S Mueller","year":"2009","unstructured":"Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics. 2009;6(3):570\u201386.","journal-title":"Neurotherapeutics"},{"issue":"8","key":"2399_CR2","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1245\/s10434-007-9438-0","volume":"14","author":"J Gnerlich","year":"2007","unstructured":"Gnerlich J, Jeffe DB, Deshpande AD, Beers C, Zander C, Margenthaler JA. Surgical removal of the primary tumor increases overall survival in patients with metastatic breast Cancer: analysis of the 1988\u20132003 SEER data. Ann Surg Oncol. 2007;14(8):2187\u201394.","journal-title":"Ann Surg Oncol"},{"key":"2399_CR3","doi-asserted-by":"crossref","unstructured":"Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg. 2004;240(6):1052\u201364.","DOI":"10.1097\/01.sla.0000145964.08365.01"},{"key":"2399_CR4","doi-asserted-by":"crossref","unstructured":"Verheij M, Jansen EP, Cats A, van Grieken NC, Aaronson NK, Boot H, Lind PA, Meershoek\u2013Klein Kranenbarg E, Nordsmark M, Putter H. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: first results from the CRITICS study. In.: Proc Am Soc Clin Oncol; 2016.","DOI":"10.1093\/annonc\/mdw237.02"},{"issue":"3","key":"2399_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/mi.7.3.6","volume":"7","author":"Y Chen","year":"2007","unstructured":"Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St Clair DK. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv. 2007;7(3):147\u201356.","journal-title":"Mol Interv"},{"issue":"5","key":"2399_CR6","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho K, Wang X, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14(5):1310\u20136.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2399_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3109\/09687688.2010.510804","volume":"27","author":"RN Saha","year":"2010","unstructured":"Saha RN, Vasanthakumar S, Bende G, Snehalatha M. Nanoparticulate drug delivery systems for cancer chemotherapy. Mol Membr Biol. 2010;27(7):215\u201331.","journal-title":"Mol Membr Biol"},{"issue":"9","key":"2399_CR8","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1089\/ars.2011.3965","volume":"15","author":"LA Gilliam","year":"2011","unstructured":"Gilliam LA, St. Clair DK. Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal. 2011;15(9):2543\u201363.","journal-title":"Antioxid Redox Signal"},{"key":"2399_CR9","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1188\/08.ONF.916-920","volume":"35","author":"JS Myers","year":"2008","unstructured":"Myers JS, Pierce J, Pazdernik T. Neurotoxicology of chemotherapy in relation to cytokine release, the blood-brain barrier, and cognitive impairment. Oncol Nurs Forum. 2008;35:916\u201320.","journal-title":"Oncol Nurs Forum"},{"key":"2399_CR10","doi-asserted-by":"crossref","unstructured":"Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267\u201385.","DOI":"10.2174\/092986709788803312"},{"key":"2399_CR11","unstructured":"Partridge M, Li S-R, Pateromichelakis S, Francis R, Phillips E, Huang XH, et al. Detection of minimal residual cancer to investigate why oral tumors recur despite seemingly adequate treatment. Clin Cancer Res. 2000;6(7):2718\u201325."},{"issue":"6","key":"2399_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.ccr.2006.11.008","volume":"10","author":"D Hambardzumyan","year":"2006","unstructured":"Hambardzumyan D, Squartro M, Holland EC. Radiation resistance and stem-like cells in brain tumors. Cancer Cell. 2006;10(6):454\u20136.","journal-title":"Cancer Cell"},{"key":"2399_CR13","doi-asserted-by":"crossref","unstructured":"P\u00e0ez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vi\u00f1als F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15(3):220\u201331.","DOI":"10.1016\/j.ccr.2009.01.027"},{"key":"2399_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev-pathol-121808-102109","volume":"5","author":"CL Gladson","year":"2010","unstructured":"Gladson CL, Prayson RA, Liu WM. The pathobiology of glioma tumors. Annu Rev Pathol: Mech Dis. 2010;5:33\u201350.","journal-title":"Annu Rev Pathol: Mech Dis"},{"issue":"5","key":"2399_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrc2818","volume":"10","author":"JT Huse","year":"2010","unstructured":"Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10(5):319\u201331.","journal-title":"Nat Rev Cancer"},{"key":"2399_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1146\/annurev.pathol.1.110304.100043","volume":"1","author":"DN Louis","year":"2006","unstructured":"Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol Mech Dis. 2006;1:97\u2013117.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"2399_CR17","doi-asserted-by":"crossref","unstructured":"Stummer W, Reulen H-J, Meinel T, Pichlmeier U, Schumacher W, Tonn J-C, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564\u201376.","DOI":"10.1227\/01.neu.0000317304.31579.17"},{"key":"2399_CR18","doi-asserted-by":"crossref","unstructured":"Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190\u20138.","DOI":"10.3171\/jns.2001.95.2.0190"},{"issue":"6","key":"2399_CR19","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO;2-D","volume":"74","author":"MS Berger","year":"1994","unstructured":"Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer. 1994;74(6):1784\u201391.","journal-title":"Cancer"},{"key":"2399_CR20","doi-asserted-by":"crossref","unstructured":"Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572\u20132.","DOI":"10.1200\/JCO.1999.17.8.2572"},{"issue":"3","key":"2399_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/neuonc\/nor218","volume":"14","author":"KR Yabroff","year":"2012","unstructured":"Yabroff KR, Harlan L, Zeruto C, Abrams J, Mann B. Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006. Neuro-Oncology. 2012;14(3):351\u20139.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"2399_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nbd.2003.12.016","volume":"16","author":"P Ballabh","year":"2004","unstructured":"Ballabh P, Braun A, Nedergaard M. The blood\u2013brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16(1):1\u201313.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"2399_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1124\/pr.57.2.4","volume":"57","author":"BT Hawkins","year":"2005","unstructured":"Hawkins BT, Davis TP. The blood-brain barrier\/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173\u201385.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2399_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrn1824","volume":"7","author":"NJ Abbott","year":"2006","unstructured":"Abbott NJ, R\u00f6nnb\u00e4ck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41\u201353.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"2399_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1602\/neurorx.2.1.3","volume":"2","author":"WM Pardridge","year":"2005","unstructured":"Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005;2(1):3\u201314.","journal-title":"NeuroRx"},{"key":"2399_CR26","doi-asserted-by":"crossref","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429\u201334.","DOI":"10.1158\/1078-0432.CCR-06-3045"},{"issue":"2","key":"2399_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","volume":"115","author":"R Dent","year":"2009","unstructured":"Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423\u20138.","journal-title":"Breast Cancer Res Treat"},{"key":"2399_CR28","doi-asserted-by":"crossref","unstructured":"Liedtke C, Mazouni C, Hess KR, Andr\u00e9 F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275\u201381.","DOI":"10.1200\/JCO.2007.14.4147"},{"key":"2399_CR29","doi-asserted-by":"crossref","unstructured":"Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652\u20137.","DOI":"10.1200\/JCO.2006.06.5664"},{"issue":"11","key":"2399_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2009.08.004","volume":"30","author":"Y Malam","year":"2009","unstructured":"Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009;30(11):592\u20139.","journal-title":"Trends Pharmacol Sci"},{"issue":"5665","key":"2399_CR31","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818\u201322.","journal-title":"Science"},{"key":"2399_CR32","doi-asserted-by":"crossref","unstructured":"Liu Y, Mei L, Xu C, Yu Q, Shi K, Zhang L, et al. Dual receptor recognizing cell penetrating peptide for selective targeting, efficient intratumoral diffusion and synthesized anti-glioma therapy. Theranostics. 2016;6(2):177\u201391.","DOI":"10.7150\/thno.13532"},{"key":"2399_CR33","unstructured":"Wang X, Qiu Y, Yu Q, Li H, Chen X, Li M, et al. Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity. Int J Pharm. 2017"},{"issue":"1","key":"2399_CR34","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/1471-2407-8-228","volume":"8","author":"K Tao","year":"2008","unstructured":"Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 2008;8(1):228.","journal-title":"BMC Cancer"},{"key":"2399_CR35","doi-asserted-by":"crossref","unstructured":"Liu Y, Mei L, Yu Q, Zhang Q, Gao H, Zhang Z, et al. Integrin \u03b1v\u03b23 targeting activity study of different retro-inverso sequences of RGD and their potentiality in the designing of tumor targeting peptides. Amino Acids. 2015;47(12):2533\u20139.","DOI":"10.1007\/s00726-015-2043-9"},{"issue":"2","key":"2399_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1634\/theoncologist.9-2-197","volume":"9","author":"A Broniscer","year":"2004","unstructured":"Broniscer A, Gajjar A. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist. 2004;9(2):197\u2013206.","journal-title":"Oncologist"},{"key":"2399_CR37","doi-asserted-by":"crossref","unstructured":"Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the glioma outcomes project. J Neurosurg. 2003;99(3):467\u201373.","DOI":"10.3171\/jns.2003.99.3.0467"},{"key":"2399_CR38","doi-asserted-by":"crossref","unstructured":"Proia TA, Keller PJ, Gupta PB, Klebba I, Jones AD, Sedic M, et al. Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell. 2011;8(2):149\u201363.","DOI":"10.1016\/j.stem.2010.12.007"},{"key":"2399_CR39","doi-asserted-by":"crossref","unstructured":"Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem\/progenitor cells. Genes Dev. 2003;17(10):1253\u201370.","DOI":"10.1101\/gad.1061803"},{"key":"2399_CR40","doi-asserted-by":"crossref","unstructured":"Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, et al. Hypoxia-inducible factor 1\u03b1 promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res. 2012;14(1):R6.","DOI":"10.1186\/bcr3087"},{"issue":"17","key":"2399_CR41","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","volume":"26","author":"CE Eyler","year":"2008","unstructured":"Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol. 2008;26(17):2839\u201345.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2399_CR42","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc1590","volume":"5","author":"M Dean","year":"2005","unstructured":"Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5(4):275\u201384.","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2399_CR43","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.drup.2010.08.001","volume":"13","author":"L Lacerda","year":"2010","unstructured":"Lacerda L, Pusztai L, Woodward WA. The role of tumor initiating cells in drug resistance of breast cancer: implications for future therapeutic approaches. Drug Resist Updat. 2010;13(4):99\u2013108.","journal-title":"Drug Resist Updat"},{"key":"2399_CR44","doi-asserted-by":"crossref","unstructured":"Shaw FL, Harrison H, Spence K, Ablett MP, Sim\u00f5es BM, Farnie G, et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012;17(2):111\u20137.","DOI":"10.1007\/s10911-012-9255-3"},{"issue":"11","key":"2399_CR45","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s11095-007-9303-7","volume":"24","author":"LN Patel","year":"2007","unstructured":"Patel LN, Zaro JL, Shen W-C. Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res. 2007;24(11):1977\u201392.","journal-title":"Pharm Res"},{"issue":"11","key":"2399_CR46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.addr.2009.06.001","volume":"61","author":"SB Fonseca","year":"2009","unstructured":"Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev. 2009;61(11):953\u201364.","journal-title":"Adv Drug Deliv Rev"},{"issue":"28","key":"2399_CR47","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.2174\/138161205774580796","volume":"11","author":"S El-Andaloussi","year":"2005","unstructured":"El-Andaloussi S, Holm T, Langel U. Cell-penetrating peptides: mechanisms and applications. Curr Pharm Des. 2005;11(28):3597\u2013611.","journal-title":"Curr Pharm Des"},{"issue":"3","key":"2399_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol. 2000;182(3):311\u201322.","journal-title":"J Cell Physiol"},{"issue":"3","key":"2399_CR49","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1016\/S0022-5347(01)65703-3","volume":"156","author":"M-C Bettencourt","year":"1996","unstructured":"Bettencourt M-C, Bauer JJ, Sesterhenn IA, Mostofi F, McLeod DG, Moul JW. Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. J Urol. 1996;156(3):1064\u20138.","journal-title":"J Urol"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-018-2399-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-018-2399-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T19:36:59Z","timestamp":1556221019000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-018-2399-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,26]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2399"],"URL":"https:\/\/doi.org\/10.1007\/s11095-018-2399-0","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,26]]},"assertion":[{"value":"14 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"130"}}